EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY 4.0

International Anal Neoplasia Society's consensus guidelines for anal cancer screening

Elizabeth A Stier iD, Megan A Clarke iD, Ashish A Deshmukh iD, Nicolas Wentzensen iD, Yuxin Liu iD, I Mary Poynten iD, Eugenio Nelson Cavallari, Valeria Fink, Luis F Barroso, Gary M Clifford iD, Tamzin Cuming, Stephen E Goldstone und 7 weitere

International Journal of Cancer · 15.05.2024 · 154 (10) · 1694-1702

DOI: 10.1002/ijc.34850 ↗

Kurz gefasst

Leitlinie in der Zeitschrift International Journal of Cancer, online erschienen am 31.01.2024. Verfasst von Elizabeth A Stier und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Papillomavirus Infections, Sexual and Gender Minorities, Anus Neoplasms, HIV Infections. Die Arbeit wurde bisher 317-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The International Anal Neoplasia Society (IANS) developed consensus guidelines to inform anal cancer screening use among various high‐risk groups. Anal cancer incidence estimates by age among risk groups provided the basis to identify risk thresholds to recommend screening. Guided by risk thresholds, screening initiation at age 35 years was recommended for men who have sex with men (MSM) and transgender women (TW) with HIV. For other people with HIV and MSM and TW not with HIV, screening initiation at age 45 years was recommended. For solid organ transplant recipients, screening initiation beginning from 10 years post‐transplant was recommended. For persons with a history of vulvar precancer or cancer, screening initiation was recommended starting within 1 year of diagnosis of vulvar precancer or cancer. Persons aged ≥45 years with a history of cervical/vaginal HSIL or cancer, perianal warts, persistent (>1 year) cervical HPV16, or autoimmune conditions could be considered for screening with shared decision‐making, provided there is adequate capacity to perform diagnostic procedures (high‐resolution anoscopy [HRA]). Anal cytology, high‐risk (hr) human papillomavirus (HPV) testing (including genotyping for HPV16), and hrHPV‐cytology co‐testing are different strategies currently used for anal cancer screening that show acceptable performance. Thresholds for referral for HRA or follow‐up screening tests are delineated. These recommendations from IANS provide the basis to inform management of abnormal screening results, considering currently available screening tools. These guidelines provide a pivotal foundation to help generate consensus among providers and inform the introduction and implementation of risk‐targeted screening for anal cancer prevention.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Papillomavirus InfectionsSexual and Gender MinoritiesAnus NeoplasmsHIV InfectionsMaleHumansFemaleAdultMiddle AgedHomosexuality, MaleEarly Detection of CancerHuman papillomavirus 16Papillomaviridae

Stichwörter der Autor:innen

anal HPVanal canceranal cancer screeninganal cytology

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Division of Cancer Epidemiology & Genetics, National Cancer Institute, Rockville, Maryland, USA.
  • Department of Public Health Sciences, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia.

ORCID-Profile: Elizabeth A Stier, Megan A Clarke, Ashish A Deshmukh, Nicolas Wentzensen, Yuxin Liu, I Mary Poynten, Gary M Clifford, Jennifer M Roberts

Förderung

  • World Health Organization

Zitieren

APA

Stier, E. A., Clarke, M. A., Deshmukh, A. A., Wentzensen, N., Liu, Y., Poynten, I. M., Cavallari, E. N., Fink, V., Barroso, L. F., Clifford, G. M., Cuming, T., Goldstone, S. E., Hillman, R. J., Rosa-Cunha, I., La Rosa, L., Palefsky, J. M., Plotzker, R., Roberts, J. M., & Jay, N. (2024). International Anal Neoplasia Society's consensus guidelines for anal cancer screening. International Journal of Cancer, 154(10), 1694-1702. https://doi.org/10.1002/ijc.34850

Vancouver

Stier EA, Clarke MA, Deshmukh AA, Wentzensen N, Liu Y, Poynten IM, et al. International Anal Neoplasia Society's consensus guidelines for anal cancer screening. International Journal of Cancer. 2024;154(10):1694-1702. doi:10.1002/ijc.34850

BibTeX
@article{Stier2024,
  author = {Stier, Elizabeth A and Clarke, Megan A and Deshmukh, Ashish A and Wentzensen, Nicolas and Liu, Yuxin and Poynten, I Mary and Cavallari, Eugenio Nelson and Fink, Valeria and Barroso, Luis F and Clifford, Gary M and Cuming, Tamzin and Goldstone, Stephen E and Hillman, Richard J and Rosa-Cunha, Isabela and La Rosa, Luciana and Palefsky, Joel M and Plotzker, Rosalyn and Roberts, Jennifer M and Jay, Naomi},
  title = {International Anal Neoplasia Society's consensus guidelines for anal cancer screening},
  journal = {International Journal of Cancer},
  year = {2024},
  volume = {154},
  number = {10},
  pages = {1694--1702},
  doi = {10.1002/ijc.34850}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche